Prognostic significance of p53, bcl-2, vimentin, and S100 protein- positive langerhans cells in endometrial carcinoma

Human Pathology

Volumn 29, Issue 5, 1998, Pages 455-462

  Coppola, Domenico ^a   Fu, Ling ^b   Nicosia, Santo V ^b   Kounelis, Sophia ^b   Jones, Mirka ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NONE

Author keywords

Bcl 2; Endometrial carcinoma; Langerhans cells; P53; Vim

Indexed keywords

PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100; VIMENTIN;

ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0031896891     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90060-0     Document Type: Article

References (49)

1. Lane DP, Benchimol S: P53: Oncogene or anti-oncogene? Gene Dev 4:1-8, 1990
2. Kern SE, Peitenpol JA, Thiagalingam S, et al: Oncogenic forms of P53 inhibit P53-regulated gene expression. Science 256:827-830, 1990
3. Jiko K, Sasano H, Ito K, et al: Immunohistochemical and in situ hybridization analysis of P53 in human endometrial carcinoma of the uterus. Anticancer Res 13:305-310, 1993
4. Lukes AS, Kohler MF, Pieper CF, et al: Multivariable analysis of DNA ploidy, P53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73:2380-2385, 1994
5. Ito K, Watanabe K, Nasim S, et al: Prognostic significance of P53 overexpression in endometrial cancer. Cancer Res 54:4667-4670, 1994
6. Reinartz JJ, George E, Lindgren BR, et al: Expression of P53, transforming growth factor alpha, epidermal growth factor receptor, and c-erb-2 in endometrial carcinoma and correlation with survival and known predictors of survival. HUM PATHOL 25:1075-1083, 1994
7. Inoue M, Okayama A, Fujita M, et al: Clinicopathological characteristics of P53 overexpression in endometrial cancers. Int J Cancer 58:14-19, 1994
8. Nielsen AL, Nyholm HC: P53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type: An immunohistochemical examination on paraffin sections. Am J Clin Pathol 102:76-79, 1994
9. Enomoto T, Fujita M, Inoue M, et al: Alteration of the P53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado. Am J Clin Pathol 103:224-230, 1995
10. Ngan BY, Chen-Levy Z, Weiss LM, et al: Expression in non-Hodgkin's lymphoma of the Bcl-2 protein associated with the (14:18) translocation. N Engl J Med 318:1638-1644, 1988
11. Bissonnette R, Echeverri F, Mahboubi A, et al: Apoptotic cell death induced by c-myc is inhibited by Bcl-2. Nature (Lond) 359:552-554, 1992
12. Fanidi A, Harrington EA, Evan GL: Cooperative interaction between c-myc and Bcl-2 protooncogene. Nature (Lond) 59:554-556, 1992
13. Gompel A, Sabowein JC, Martin A, et al: Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 144:1195-1202, 1994
14. Chhieng DC, Ross JS, Ambros RA: Bcl-2 expression and the development of endometrial carcinoma. Mod Pathol 9:402-406, 1996
15. Gould VE: Histogenesis and differentiation: A reevaluation of these concepts as criteria for the classification of tumors. HUM PATHOL 17:212-214, 1987
16. Donhuijsen K, Schulz S: Prognostic significance of vimentin positivity in formalin-fixed renal cell carcinoma. Pathol Res Pract 184:287-291, 1989
17. Cantoretti G, Andreola S, Clemente C, et al: Vimentin and P53 expression on epidermal growth receptor-positive, estrogen receptor-negative breast carcinomas. Br J Cancer 57:353-357, 1988
18. Dabbs DJ, Geisinger KR, Norris HT: Intermediate filaments in endometrial and endocervical carcinomas: The diagnostic utility of vimentin patterns. Am J Surg Pathol 10:568-576, 1986
19. Hammar S, Bockus D, Remington F, et al: The widespread distribution of Langerhans cells in pathologic issues: An ultrastructural and immunohistochemical study. HUM PATHOL 17:894-905, 1986
20. Houck JR, Motsay SJ, Bartholomew M, et al: Prognostic implications of inflammatory cell infiltrates in squamous cell carcinoma of the head and neck (meeting abstract). Third International Head and Neck Oncology Research Conference 1990, Las Vegas, NV, The American Society for Head and Neck Surgery, A7.4
21. Tsujitani S, Furukawa T, Tamada R, et al: Langerhans cells and prognosis in patients with gastric carcinoma. Cancer 59:501-505, 1987
22. Schroder S, Dralle H, Bay V, et al: Immunohistology and prognosis in thyroid cancer: Determination of the malignant potential of papillary and medullary neoplasms by detection of S-100 protein and Leu-Ml antigen. Acta Med Aust 16:2-5, 1989
23. Oka K, Nakano T, Arai T: Adenocarcinoma of the cervix treated with radiation alone: Prognostic significance of S-100 protein and vimentin immunostaining. Obstet Gynecol 79:347-350, 1992
24. Shi SR, Key ME, Kalza KL: Antigen retrieval in formalin-fixed paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741-748, 1991
25. Kern SE, Kinzler KW, Bruskin A, et al: Identification of P53 as a sequence-specific DNA-binding protein. Science 252:1708-1711, 1991
26. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821-1828, 1994
27. El-Deiry WS, Tokino T, Velculescu VE, et al: WAT-1, a potential mediator of P53 tumor suppression. Cell 75:817-825, 1993
28. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of P53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
29. Lowe SW, Ruley HE, Jacks T, et al: P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1994
30. Lowe SW, Bodis S, McClatchey A, et al: P53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
31. Kinzler KW, Vogelstein B: Cancer therapy meets p53. N Engl J Med 331:49-50, 1994
32. Hall PA, Lane DP: P53 in tumor pathology: Can we trust immunohistochemistry? - revisited! J Pathol 172:1-4, 1994
33. Bronner M, Culin C, Reed J, et al: Bcl-2 protooncogene and the gastrointestinal mucosal epithelial tumor progression model as related to proposed morphologic and molecular oncogenetic sequences. Lab Invest 68:43A, 1993 (abstr)
34. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992
35. Lu QL, Elia G, Lucas S, et al: Bcl-2 protooncogene-expression in Epstein-Barr virus associated nasopharyngeal carcinoma. Int J Cancer 53:29-35, 1993
36. Bhargava V, Kell DL, Van de Rijn M, et al: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535-540, 1994
37. Pezzella F, Turley H, Kuzu I, et al: Bcl-2 protein in non small cell lung carcinoma. N Engl J Med 329:690-694, 1993
38. Monaghan P, Roberston D, Amos TAS, et al: Ultrastructural localization of Bcl-2 protein. J Histochem Cytochem 40:1819-1825, 1992
39. Leader M, Collins M, Patel J, et al: Vimentin: An evaluation of its role as a tumor marker. Histopathology 11:63-72, 1987
40. Azumi N, Battifora H: The distribution of Vimentin and keratin in epithelial and nonepithelial neoplasms: A comprehensive immunohistochemical study on formalin and alcohol fixed tumors. Am J Clin Pathol 88:286-296, 1987
41. Ohwada M, Suzaki M, Tamada T: Immunohistochemical investigation of vimentin of uterine endometrial and endocervical adenocarcinoma. Acta Obstet Gynaecol Jpn 42:1237-1243, 1990
42. Raymond W, Leeng ASY: Vimentin: A new prognostic parameter in breast carcinoma? J Pathol 158:107-114, 1989
43. Domagala W, Lasota J, Dukowicz A, et al: Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol 137:1299-1304, 1990
44. Real FX, Furukawa KS, Mattes MJ, et al: Class I (unique) tumor antigens of human melanoma: Identification of unique and common epitopes on a 90 kDa glycoprotein. Proc Natl Acad Sci U S A 85:3965-3969, 1988
45. Muul LM, Spiess PJ, Director EP, et al: Identification of specific cytolytic immune response against autologous tumor in humans bearing malignant melanoma. J Immunol 138:989-995, 1987
46. Morris HHB, Gatter KC: Langerhans cells in human cervical epithelium: An immunohistological study. Br J Obstet Gynaecol 90:400-411, 1983
47. Shelley WB, Juhlin L: Langerhans cells form a reticuloepithelial trap for external contact antigen. Nature 261:46-47, 1976
48. Stingl G, Wolff-Schreiner EC, Pickler WJ, et al: Epidermal Langerhans cells bear Fc and C3 receptors. Nature 268:245-246, 1977
49. Rowden G, Lewis MG, Sullivan AK: Ia antigen expression on human Langerhans cells. Nature 268:247-248, 1977